Search

Boehringer Ingelheim announces 2018 BVDzero Case Awards

Boehringer Ingelheim announces 2018 BVDzero Case Awards Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered Applications can be submitted on www.bvdzero.com

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D

New biomass power plant Ingelheim

Boehringer Ingelheim produces its own green energy

European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares

European Commission grants marketing authorization for spesolimab, the first specific treatment option for generalized pustular psoriasis flares in adults

CHMP recommends conditional approval for first GPP treatment

CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares

World Rabies Day: BI fights rabies misconceptions

Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.

Global language learning platform for our people

One global learning platform for languages, countless opportunities to grow your career

Largest European development center for biotechnology

Boehringer Ingelheim inaugurates largest European development center for biotechnology

bix_facilitates_global_partnerships

BI X focuses on partnerships to speed up the development of digital healthcare solutions

Investment of 65 million euro in avian vaccines in France

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines

digital_leader_award_2020

Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award

New partnership to develop schizophrenia treatments

Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments

Bluetongue disease

The bluetongue virus is a viral disease that affects ruminants' health. It doesn't affect humans, but it is a threat to animals.

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.

Boehringer receives SBTi validation for CO2 reduction targets

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

Data science, agile working, UX design: our evolving IT careers

Meet our IT colleagues working in the fields of user experience, data science and agile development

FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs

Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program

Phase 1 start of treatment for Geographic Atrophy patients

Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)

Second cancer immunotherapy partnership with 3T Bio

Accelerating new cancer medicines in partnership with CBmed

Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients

Boehringer Ingelheim 2022 half year results

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor

It is about saving lives Alexis Jaliquias feline blood bank

Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America

Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU

Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU

Acquisition Saint-Herblon site and Coophavet brand

Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers